Viking Therapeutics logo

Viking Therapeutics

VKTX | NASDAQ
Chart Builder DCF Calculator
$26.80
-$2.42 (-8.28%)
At close: Nov 16, 2026, 4:00 PM ET
$26.73
-$0.07 (-0.26%)
After-hours: Nov 16, 2026, 7:57 PM ET
-8.28%

Rating

Updated: Nov 16, 2026
29.1
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #831/1021 (Top 81%)

Key Statistics

Market Data

Market Cap $3.42B
1D Range
26.44 28.58
52W Range
24.21 42.13

Valuation (TTM)

PE -4.96
PB 5.81
EV/EBITDA -4.33

Valuation (NTM)

Forward PE N/A
Forward PEG -0.06
Price Target $87.00
Loading financial charts...

Profile

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investi...

Sector Healthcare
Industry Biotechnology
Employees 53
IPO Date Apr 28, 2015
Fiscal Year January - December

Latest News

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026

1 day ago · gurufocus.com

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028

3 days ago · fool.com

Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
Viking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55

5 days ago · fxempire.com

Viking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026

8 days ago · prnewswire.com

Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026

12 days ago · fool.com

Here's the 1 Stock I'd Most Want to Buy If the Market Crashes
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.

13 days ago · fool.com

Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
Viking Therapeutics to Participate at Upcoming Investor Conferences

13 days ago · prnewswire.com

Viking Therapeutics to Participate at Upcoming Investor Conferences
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?

18 days ago · zacks.com

VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

18 days ago · zacks.com

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses

19 days ago · zacks.com

VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$87.00
Upside
+224.63%
Buy (6)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.